Comparison of clinical and biochemical characteristics of patients who died and those of patients who survived the initial 3-month period
| Dead (n = 34) | Alive (n = 274) | p Value | Likelihood ratio | |
|---|---|---|---|---|
| GI, gastrointestinal; INR, international normalisation ratio; MELD, model for end-stage liver disease. | ||||
| *As defined by serum creatinine ⩾1.5 mg/dl. | ||||
| †All patients had type 2 hepatorenal syndrome. | ||||
| Age (years) | 53 (8) | 52 (9) | 0.37 | |
| Ascites | 33 (97%) | 238 (87%) | ||
| Controlled | 6 (18%) | 106 (44%) | 0.004 | 7.25 |
| Uncontrolled | 27 (82%) | 132 (56%) | ||
| Hepatic encephalopathy | 18 (53%) | 127 (46%) | 0.58 | 0.49 |
| GI bleeding | 10 (29%) | 81 (29%) | 0.57 | 0.001 |
| SBP | 12 (35%) | 71 (26%) | 0.37 | |
| Renal failure* | 6 (17%) | 33 (12%) | 0.48 | 0.77 |
| Hepatorenal syndrome† | 6 (17%) | 14 (5%) | 0.026 | 5.21 |
| Bilirubin (mg/dl) | 8.5 (8.4) | 3.6 (3.1) | 0.000 | |
| Albumin (g/l) | 28 (5) | 31 (5) | 0.000 | |
| INR | 1.8 (0.5) | 1.6 (0.9) | 0.025 | |
| Creatinine (mg/dl) | 1 (0.3) | 1.2 (1.1) | 0.416 | |
| Sodium (mEq/l) | 130 (6) | 136 (4) | 0.000 | |
| MELD score | 21 (5) | 16 (5) | 0.000 | |